Introduction
Cell and gene therapy regulatory affairs specialist is a title that has gone from rare to increasingly common across biotech hiring boards over the past several years, as the number of approved and investigational cell and gene therapies has grown well beyond the handful of pioneering products that defined the field a decade ago. For regulatory professionals considering a move into this space, or for biologics specialists wondering whether the jump is worth it, it helps to understand what actually separates this work from traditional drug or biologics regulatory affairs, because the differences are substantial even though the job title looks similar on paper.
The role exists because cell and gene therapies, autologous CAR-T products, viral vector gene therapies, allogeneic cell therapies, and gene-edited products among them, raise regulatory questions that conventional small-molecule or even monoclonal antibody frameworks were never built to answer. Manufacturing is frequently patient-specific or batch-limited, long-term safety follow-up can extend over many years, and the science itself is still evolving quickly enough that guidance documents are sometimes written in response to a specific product rather than ahead of it.
Where the Role Sits in the Organization
Most cell and gene therapy regulatory specialists work inside a dedicated regulatory affairs function within a biotech company, though the group is often smaller and flatter than a traditional pharma regulatory department given how much of the industry is still composed of mid-size and early-stage companies. The role sits in close, near-daily contact with CMC, nonclinical toxicology, clinical development, and manufacturing, because regulatory strategy in this space is inseparable from manufacturing reality in a way that doesn't apply as directly to a conventional tablet or injectable.
It's also a role that tends to carry outsized influence relative to seniority. Because the regulatory pathway for a given product is often genuinely unsettled, a specialist's read on how a health authority is likely to view a particular manufacturing change or trial design question can shape program decisions well above what the title alone would suggest.
What the Work Actually Looks Like
A large share of the job involves preparing and maintaining the regulatory submissions that support early and ongoing clinical development: investigational new drug applications and their amendments, responses to clinical hold questions, and the CMC sections that document a manufacturing process which, for many cell and gene products, is still being refined even as patients are being dosed. Writing CMC content for a process that changes between clinical phases, sometimes substantially, is one of the more distinctive parts of this work compared to traditional regulatory affairs.
Specialists also spend meaningful time preparing for and participating in formal meetings with health authorities, since early and frequent regulatory interaction is far more central to cell and gene therapy development than it is to most conventional drug programs. These meetings often address questions that don't have an established template answer: how much comparability data is needed to bridge a manufacturing change, what nonclinical model is appropriate for a novel vector, how a long-term follow-up study for genomic safety should be designed. Preparing a sponsor's position on questions like these, and anticipating where a reviewer is likely to push back, is a recurring and intellectually demanding part of the role.
Long-term follow-up planning is its own distinct workstream. Many gene therapies carry expectations for safety monitoring that extend five, ten, or in some cases fifteen years past treatment, and the regulatory specialist is typically involved in designing how that follow-up program is structured, documented, and reported, which requires thinking in a very different time horizon than most regulatory work demands.
Labeling and risk management planning round out the role, often including a risk evaluation and mitigation strategy or comparable program given the novel and sometimes serious risks these therapies can carry, along with the patient and provider education materials that accompany a complex, often one-time treatment.
The Judgment Calls That Define the Role
Because so much of the regulatory framework for cell and gene therapies has developed alongside the products themselves rather than well ahead of them, specialists spend a lot of time interpreting guidance that is recent, incomplete, or still being clarified through actual health authority interactions rather than settled precedent. That means building regulatory strategy on a mix of published guidance, informal agency signals from meetings, and comparison to how similar products have been handled, while being honest internally about how much of that strategy rests on inference rather than established rule.
There's also a constant tension between manufacturing evolution and regulatory stability. A process improvement that makes a therapy more scalable or affordable to produce can trigger comparability questions that slow a program down, and specialists are regularly the ones weighing whether a given change is worth that regulatory cost at a particular point in development.
Skills That Separate Strong Performers
Comfort with genuine scientific ambiguity is probably the single biggest differentiator. Specialists who need a clear precedent before they can form a regulatory position struggle in a field where precedent is often thin. The strongest performers can reason from first principles about risk and evidence, build a defensible position, and still hold that position loosely enough to adjust as agency feedback or new data comes in.
Deep comfort with CMC and manufacturing science also matters more here than in most regulatory specialties, since a meaningful share of the regulatory risk in cell and gene therapy programs originates in manufacturing rather than in clinical or nonclinical data. Specialists who can engage substantively with process development teams, not just translate their output into submission language, tend to add more value and build more credibility internally.
Career Paths Into and Out of the Role
People move into this specialty from a few directions: regulatory professionals with a biologics or CMC background who build cell and gene-specific expertise through direct program experience, scientists from manufacturing or process development who move into regulatory affairs, and occasionally clinical operations professionals who've worked closely on cell and gene therapy trials. Formal cell and gene-specific training exists but is still less standardized than training for more established therapeutic areas, so most expertise in this field is still built on the job.
From the role, common next steps include regulatory strategy leadership for a broader cell and gene therapy portfolio, CMC-focused regulatory leadership roles, or a move into regulatory consulting, which carries steady demand given how many smaller biotech companies are developing their first cell or gene therapy product without in-house expertise to guide them.
How the Role Changes With Company Size
At a larger, more established cell and gene therapy company, the specialist usually works within a more defined regulatory function with precedent from the company's own earlier programs to draw on, along with dedicated CMC regulatory support. The work is still demanding but benefits from institutional memory that a newer company simply doesn't have yet.
At an early-stage biotech advancing its first cell or gene therapy candidate, the specialist is frequently building regulatory strategy with far less internal precedent, often as one of only a few regulatory people in the entire company, which means broader scope, more direct contact with leadership, and less room to specialize narrowly.
Common Misconceptions About the Role
A common misconception is that this role is simply biologics regulatory affairs with a different product category attached. In practice, the manufacturing variability, the long-term follow-up obligations, and the comparative thinness of established guidance make the day-to-day reasoning genuinely different, even when the submission formats look similar on the surface.
Another misconception is that the role is primarily about navigating accelerated approval pathways and designations. Those pathways matter and specialists do work with them, but a large share of the actual workload is unglamorous CMC documentation, comparability assessment, and long-term safety program design that doesn't show up in headlines about breakthrough therapies.
How the Role Interacts With the Broader Field
Specialists in this space tend to track scientific and regulatory developments more actively than regulatory professionals in more mature therapeutic areas, since guidance and agency thinking continue to evolve meaningfully year over year. Following new guidance documents, public workshops, and how recent product approvals were handled is less optional background reading here than it is in established areas of drug regulation, because yesterday's precedent can shift faster than in most other parts of the field.
Cross-functional fluency with manufacturing and clinical teams also tends to run deeper than in other regulatory specialties, simply because the three functions are so tightly coupled in this kind of product development. Specialists who build genuine working relationships across those teams, rather than treating them as internal clients to manage, tend to produce stronger regulatory strategy.
Conclusion
The cell and gene therapy regulatory affairs specialist role suits people who find real satisfaction in building a defensible position on genuinely open questions rather than applying a well-worn playbook. It's intellectually demanding, closely tied to the science and manufacturing behind the product, and still growing as more of these therapies move through development, which makes it one of the more dynamic specializations available to a regulatory professional willing to work without a fully settled rulebook.